Search

Your search keyword '"Campos M"' showing total 28 results
Start Over Author "Campos M" Journal actas dermo-sifiliograficas
28 results on '"Campos M"'

1. [Translated article] Drug Survival in Cyclosporine Treatment for Moderate to Severe Atopic Dermatitis: Analysis of the Spanish Atopic Dermatitis Registry (BIOBADATOP)

Author

Couselo-Rodríguez, C., primary, Batalla, A., additional, Carrascosa, J.M., additional, Chicharro, P., additional, González-Quesada, A., additional, de la Cueva, P., additional, Giménez-Arnau, A.M., additional, Gilaberte, Y., additional, Rodríguez-Serna, M., additional, Montero-Vilchez, T., additional, Ruiz-Villaverde, R., additional, Elosua-González, M., additional, Silvestre-Salvador, J.F., additional, Munera-Campos, M., additional, Sánchez-Pérez, J., additional, Carretero, G., additional, Mauleón-Fernández, C., additional, Curto-Barredo, L., additional, Ballano-Ruiz, A., additional, Botella-Estrada, R., additional, Arias-Santiago, S., additional, Navarro-Triviño, F.J., additional, Roustan-Gullón, G., additional, Betlloch, I., additional, del Alcázar, E., additional, Abalde-Pintos, M.T., additional, Suárez-Perez, J., additional, García-Doval, I., additional, Descalzo, M.Á., additional, and Flórez, Á., additional

Published
2024
Full Text
View/download PDF

2. Supervivencia de la ciclosporina en el tratamiento de la dermatitis atópica moderada-grave: Registro Español de Dermatitis Atópica (BIOBADATOP)

Author

Couselo-Rodríguez, C., primary, Batalla, A., additional, Carrascosa, J.M., additional, Chicharro, P., additional, González-Quesada, A., additional, de la Cueva, P., additional, Giménez-Arnau, A.M., additional, Gilaberte, Y., additional, Rodríguez-Serna, M., additional, Montero-Vilchez, T., additional, Ruiz-Villaverde, R., additional, Elosua-González, M., additional, Silvestre-Salvador, J.F., additional, Munera-Campos, M., additional, Sánchez-Pérez, J., additional, Carretero, G., additional, Mauleón-Fernández, C., additional, Curto-Barredo, L., additional, Ballano-Ruiz, A., additional, Botella-Estrada, R., additional, Arias-Santiago, S., additional, Navarro-Triviño, F.J., additional, Roustan-Gullón, G., additional, Betlloch, I., additional, del Alcázar, E., additional, Abalde-Pintos, M.T., additional, Suárez-Perez, J., additional, García-Doval, I., additional, Descalzo, M.Á., additional, and Flórez, Á., additional

Published
2024
Full Text
View/download PDF

3. Perfil epidemiológico, clínico y alérgico en pacientes con psoriasis. Evaluación del Registro Español de Dermatitis de Contacto (REIDAC)

Author

Verdaguer-Faja, J., primary, Borrego, L., additional, Mercader-García, P., additional, González Pérez, R., additional, Córdoba-Guijarro, S., additional, Giménez-Arnau, A.M., additional, Ruiz-González, I., additional, Miquel-Miquel, J., additional, Silvestre, J.F., additional, Ortiz de Frutos, F.J., additional, Tous-Romero, F., additional, Sanz Sánchez, T., additional, Rodríguez-Serna, M., additional, Sánchez-Pérez, J., additional, Serra Baldrich, E., additional, Zaragoza-Ninet, V., additional, Pastor-Nieto, M.A., additional, Gática-Ortega, M.E., additional, Sánchez Gilo, A., additional, Melé-Ninot, G., additional, Sánchez-Pedreño Guillén, P., additional, Munera-Campos, M., additional, Descalzo, M.Á., additional, García-Doval, I., additional, and Carrascosa, J.M., additional

Published
2024
Full Text
View/download PDF

7. BIOBADATOP: Registro Español de Dermatitis Atópica. Descripción y primeros resultados

Author

Munera-Campos, M., primary, Chicharro, P., additional, Gonzalez Quesada, A., additional, Florez Menendez, A., additional, de la Cueva Dovao, P., additional, Gimenez Arnau, AM., additional, Gilaberte Calzada, Y., additional, Rodríguez Serna, M., additional, Montero, T., additional, Silvestre Salvador, JF., additional, Elosua González, M., additional, del Alcazar, E., additional, Santamaría, C., additional, Sánchez-Pérez, J., additional, Carretero Hernández, G., additional, Batalla Cebey, A., additional, Jin Suh Oh, H., additional, Mauleón Fernández, C., additional, Curto Barredo, L., additional, Bertolín, M., additional, Navarro Bielsa, A., additional, Ballano Ruiz, A., additional, Botella Estrada, R., additional, Arias Santiago, S., additional, Betlloch, I., additional, Roustan Gullón, G., additional, Rosell Díaz, A., additional, Descalzo, MÁ., additional, García-Doval, I., additional, and Carrascosa, JM., additional

Published
2023
Full Text
View/download PDF

14. Cutaneous Manifestations in the Context of SARS-CoV-2 Infection (COVID-19)

Author

Carrascosa, J.M., Morillas, V., Bielsa, I., and Munera-Campos, M.

Abstract

The coronavirus 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has had enormous health, economic, and social consequences. The clinical spectrum of cutaneous manifestations observed in patients with COVID-19 is both heterogeneous and complex. To date, reports have identified 5 main categories: acral lesions, vesicular rashes, urticarial rashes, maculopapular rashes, and livedoid and necrotic lesions. However, these will probably be modified as new information comes to light. Cutaneous manifestations associated with COVID-19 probably reflect the activation of pathogenic pathways by the virus or a response to inflammatory processes, vascular or systemic complications, or even treatments. Familiarity with the cutaneous manifestations of COVID-19 may enable early diagnosis or help guide prognosis.

Published
2020
Full Text
View/download PDF

15. Innovation in Atopic Dermatitis: From Pathogenesis to Treatment

Author

Munera-Campos, M. and Carrascosa, J.M.

Abstract

Atopic dermatitis is the most common inflammatory skin disease and up to 20% of cases can be classified as moderate to severe. Our understanding of the pathogenesis of this disease has improved in recent years. The process is primarily driven by the Th2 pathway, but with significant contributions from the Th22 pathway, the Th1 and Th17 axes, epidermal barrier dysfunction, pruritus, and JAK/STAT signaling. Advances in our understanding of the pathogenesis of atopic dermatitis have led to the development of new systemic treatments. Of particular note are biologic agents targeting IL-4 and IL-13 (e. g., dupilumab, tralokinumab, and lebrikizumab) and small molecules, such as JAK inhibitors (e. g., baricitinib, upadacitinib, and abrocitinib). Novel topical treatments include phosphodiesterase 4 and JAK/STAT inhibitors. In this article, we review the main advances in the treatment of atopic dermatitis. Characterization of clinical and molecular phenotypes with a key pathogenic role is essential for driving these advances.

Published
2020
Full Text
View/download PDF

16. Perfil clínico, epidemiológico y respuesta al tratamiento, en función de la comorbilidad atópica asociada en la dermatitis atópica. Experiencia del registro BIOBADATOP

Author

Peris-Espino, V., Munera-Campos, M., Chicharro, P., Gonzalez Quesada, A., Florez Menendez, A., de la Cueva Dobao, P, Gimenez Arnau, AM., Gilaberte Calzada, Y., Rodriguez Serna, M., Montero-Vilchez, T., Silvestre Salvador, J.F., Ruiz-Villaverde, R., Elosua-Gonzalez, M., Del Alcázar-Viladomiu, E., Sánchez-Pérez, J., Carretero Hernández, G., Batalla, A., Suh Oh, H.J., Couselo-Rodríguez, C., Mauleón Fernández, C., Curto-Barredo, L., Bertolín-Colilla, M., Navarro-Bielsa, A., Ballano Ruiz, A., Botella Estrada, R., Arias-Santiago, S., Sanabria-de-la-Torre, R., Betlloch-Mas, I., Navarro-Triviño, F.J., Roustan Gullón, G., Rosell-Díaz, A., Loro-Pérez, M., Suárez-Perez, J., García-Doval, I., Descalzo-Gallego, M.Á., and Carrascosa Carrillo, J.M.

Abstract

Antecedentes: Pese al avance terapéutico en la dermatitis atópica (DA), la información sobre el impacto y la interacción con las comorbilidades atópicas (como el asma, la rinoconjuntivitis y la patología ocular) es limitada. Este estudio pretende evaluar las características clínicas y epidemiológicas de pacientes con DA, así como la respuesta al tratamiento, considerando dichas comorbilidades.

Published
2024
Full Text
View/download PDF

17. [Translated article] Epidemiological, Clinical, and Allergic Profile of Psoriatic Patients. Evaluation of the Spanish Registry of Contact Dermatitis and Cutaneous Allergy (REIDAC)

Author

Verdaguer-Faja, J., Borrego, L., Mercader-García, P., González Pérez, R., Córdoba-Guijarro, S., Giménez-Arnau, A.M., Ruiz-González, I., Miquel-Miquel, J., Silvestre, J.F., Ortiz de Frutos, F.J., Tous-Romero, F., Sanz Sánchez, T., Rodríguez-Serna, M., Sánchez-Pérez, J., Serra Baldrich, E., Zaragoza-Ninet, V., Pastor-Nieto, M.A., Gática-Ortega, M.E., Sánchez Gilo, A., Melé-Ninot, G., Sánchez-Pedreño Guillén, P., Munera-Campos, M., Descalzo, M.Á., García-Doval, I., and Carrascosa, J.M.

Abstract

Psoriasis is a chronic inflammatory dermatosis whose clinical and topographic distribution requires differential diagnosis, or the possible association with allergic contact dermatitis (ACD), requiring patch testing (PT) as part of the diagnostic procedure.

Published
2024
Full Text
View/download PDF

19. Paradoxical Reactions to Biologic Therapy in Psoriasis: A Review of the Literature

Author

Munera-Campos, M., Ballesca, F., and Carrascosa, J.M.

Abstract

Biologic drugs, which are molecules designed to act on specific immune system targets, have been shown to be very effective in treating various dermatological, rheumatological, and systemic diseases. As a group, they have an acceptable safety profile, but their use has been associated with the onset of both systemic and organ-specific inflammatory conditions. True paradoxical reactions are immune-mediated disorders that would usually respond to the biologic agent that causes them. There is still debate about whether certain other adverse reactions can be said to be paradoxical. The hypotheses proposed to explain the pathogenesis of such reactions include an imbalance in cytokine production, with an overproduction of IFN-α and altered lymphocyte recruitment and migration (mediated in part by CXCR3), and the production of autoantibodies. Some biologic therapies favor granulomatous reactions. While most of the paradoxical reactions reported have been associated with the use of TNF-α inhibitors, cases associated with more recently introduced biologic therapies —such as ustekinumab, secukinumab, and ixekizumab—are increasingly common. The study of paradoxical adverse events not only favors better management of these reactions in patients receiving biologic therapy, but also improves our knowledge of the pathogenesis of chronic inflammatory diseases and helps to identify potential therapeutic targets.

Published
2018
Full Text
View/download PDF

22. Supervivencia de la ciclosporina en el tratamiento de la dermatitis atópica moderada-grave: Registro Español de Dermatitis Atópica (BIOBADATOP)

Author

Rodríguez, C Couselo, Batalla, A, Carrascosa, JM, Chicharro, P, Quesada, A González, de la Cueva, P, Giménez-Arnau, AM, Gilaberte, Y, Serna, M Rodríguez, Vilchez, T Montero, Villaverde, R Ruiz, González, M Elosua, Silvestre-Salvador, JF, Campos, M Munera, Pérez, J Sánchez, Carretero, G, Fernández, C Mauleón, Barredo, L Curto, Ruiz, A Ballano, Estrada, R Botella, Santiago, S Arias, Navarro-Triviño, FJ, Gullón, G Roustan, Betlloch, I, Del Alcázar, E, Abalde-Pintos, MT, Perez, J Suárez, Doval, I García, Descalzo, MÁ, and Flórez, Á

Abstract

Background: The past 5 years have seen a proliferation of new treatments for atopic dermatitis (AD). We analyzed recent drug survival data for cyclosporine in this setting. Because the Spanish National Healthcare system requires patients with AD to be treated with cyclosporine before they can be prescribed other systemic treatments, drug survival for cyclosporine may be shorter than in other diseases.

Published
2023
Full Text
View/download PDF

24. [Translated article] BIOBADATOP Spanish Atopic Dermatitis Registry: Description and Early Findings

Author

Munera-Campos, M., Chicharro, P., Gonzalez Quesada, A., Flórez Menéndez, Á., de la Cueva Dobao, P., Gimenez Arnau, A.M., Gilaberte Calzada, Y., Rodríguez Serna, M., Montero-Vilchez, T., Silvestre, J.F., Elosua-González, M., del Alcázar, E., Santamaría, C., Sánchez-Pérez, J., Carretero Hernández, G., Batalla, A., Jin Suh Oh, H., Mauleón Fernández, C., Curto Barredo, L., Bertolín-Colilla, M., Navarro Bielsa, A., Ballano Ruiz, A., Botella Estrada, R., Arias Santiago, S., Betlloch, I., Roustan Gullón, G., Rosell Díaz, A., Descalzo, M.A., García-Doval, I., and Carrascosa, J.M.

Abstract

[Display omitted]

Published
2023
Full Text
View/download PDF

26. Myxoid Dermatofibrosarcoma Protuberans in Childhood

Author

Campos, M., Zarco, C., Acquadro, F., Riveiro-Falkenbach, E., and Rodríguez-Peralto, J.L.

Abstract

Dermatofibrosarcoma protuberans is a locally aggressive skin tumor that affects young and middle-aged adults. A number of histological variants have been described, the myxoid type being one of the least common. Microscopically it is formed of a neoplastic growth that is located in the dermis and hypodermis and has a predominant myxoid component. Peripherally there are infiltrating bundles of spindle-shaped cells that are diffusely positive for the CD34 immunohistochemical marker. We report a case of myxoid dermatofibrosarcoma protuberans on a finger of the left hand of a 14-year-old girl. The tumor had been present for at least 10 years. This is the first pediatric case of myxoid dermatofibrosarcoma protuberans at this site. This histological subtype has mainly been described on the extremities in adults and is very rare in children. We discuss the differential diagnosis with other CD34+myxoid mesenchymal tumors.

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results